TY - JOUR
T1 - Development of system-level performance measures for evaluation of models of care for inflammatory arthritis in Canada
AU - Barber, Claire E H
AU - Marshall, Deborah A.
AU - Mosher, Dianne P.
AU - Akhavan, Pooneh
AU - Tucker, Lori
AU - Houghton, Kristin
AU - Batthish, Michelle
AU - Levy, Deborah M.
AU - Schmeling, Heinrike
AU - Ellsworth, Janet
AU - Tibollo, Heidi
AU - Grant, Sean
AU - Khodyakov, Dmitry
AU - Lacaille, Diane
AU - Ahluwalia, Vandana
AU - Averns, Henry
AU - Barnabe, Cheryl
AU - Bombardier, Claire
AU - Bartlett, Susan J.
AU - Bernatsky, Sasha
AU - Burt, Jennifer
AU - Feldman, Debbie
AU - Gladman, Dafna D.
AU - Greene, Beverly
AU - Haraoui, Boulos
AU - Haroon, Nigil
AU - Hofstetter, Catherine
AU - Huber, Adam M.
AU - Keeling, Stephanie
AU - Lang, Bianca
AU - Le Clercq, Sharon A.
AU - Lupton, Theresa
AU - Lyddiatt, Anne
AU - Mandhane, Rashmi
AU - Morishita, Kimberly
AU - Papachristos, Angelo
AU - Patrick, Patricia
AU - Richards, Dawn
AU - Robinson, David
AU - Shiff, Natalie J.
AU - Taylor, Trudy
AU - Taylor-Gjevre, Regina
AU - Thomson, Glen T D
AU - Thorne, Carter
AU - Toupin-April, Karine
AU - Tugwell, Peter
AU - Westby, Marie D.
AU - Widdifield, Jessica
AU - Woodhouse, Linda
AU - Zummer, Michel
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Objective. To develop system-level performance measures for evaluating the care of patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. Methods. This study involved several methodological phases. Over multiple rounds, various participants were asked to help define a set of candidate measurement themes. A systematic search was conducted of existing guidelines and measures. A set of 6 performance measures was defined and presented to 50 people, including patients with IA, rheumatologists, allied health professionals, and researchers using a 3-round, online, modified Delphi process. Participants rated the validity, feasibility, relevance, and likelihood of use of the measures. Measures with median ratings ≥ 7 for validity and relevance were included in the final set. Results. Six performance measures were developed evaluating the following aspects of care, with each measure being applied separately for each type of IA except where specified: waiting times for rheumatology consultation for patients with new onset IA, percentage of patients with IA seen by a rheumatologist, percentage of patients with IA seen in yearly followup by a rheumatologist, percentage of patients with RA treated with a disease-modifying antirheumatic drug (DMARD), time to DMARD therapy in RA, and number of rheumatologists per capita. Conclusion. The first set of system-level performance measures for IA care in Canada has been developed with broad input. The measures focus on timely access to care and initiation of appropriate treatment for patients with IA, and are likely to be of interest to other arthritis care systems internationally.
AB - Objective. To develop system-level performance measures for evaluating the care of patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, and juvenile idiopathic arthritis. Methods. This study involved several methodological phases. Over multiple rounds, various participants were asked to help define a set of candidate measurement themes. A systematic search was conducted of existing guidelines and measures. A set of 6 performance measures was defined and presented to 50 people, including patients with IA, rheumatologists, allied health professionals, and researchers using a 3-round, online, modified Delphi process. Participants rated the validity, feasibility, relevance, and likelihood of use of the measures. Measures with median ratings ≥ 7 for validity and relevance were included in the final set. Results. Six performance measures were developed evaluating the following aspects of care, with each measure being applied separately for each type of IA except where specified: waiting times for rheumatology consultation for patients with new onset IA, percentage of patients with IA seen by a rheumatologist, percentage of patients with IA seen in yearly followup by a rheumatologist, percentage of patients with RA treated with a disease-modifying antirheumatic drug (DMARD), time to DMARD therapy in RA, and number of rheumatologists per capita. Conclusion. The first set of system-level performance measures for IA care in Canada has been developed with broad input. The measures focus on timely access to care and initiation of appropriate treatment for patients with IA, and are likely to be of interest to other arthritis care systems internationally.
KW - Ankylosing spondylitis
KW - Juvenile idiopathic arthritis
KW - Psoriatic arthritis
KW - Quality indicators
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=84959912279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959912279&partnerID=8YFLogxK
U2 - 10.3899/jrheum.150839
DO - 10.3899/jrheum.150839
M3 - Article
C2 - 26773106
AN - SCOPUS:84959912279
SN - 0315-162X
VL - 43
SP - 530
EP - 540
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 3
ER -